论文部分内容阅读
目的:探讨胸腺肽α1治疗对老年重症医院获得性肺炎(SHAP)患者细胞免疫功能的影响及其临床意义。方法:48例SHAP患者随机分为治疗组和对照组。治疗组在对照组基础上给予胸腺肽α1 1.6 mg皮下注射,qd,持续1周,之后改为1.6 mg,皮下注射,隔日一次,共2周。结果:治疗组治疗后单核细胞人类白细胞抗原(HLA-DR)、自然杀伤(NK)细胞、CD4+细胞及CD4+/CD8+比值明显上升;治疗组住院死亡率明显低于对照组,其存活者抗生素应用时间亦比对照组明显缩短。结论:胸腺肽α1能提高SHAP患者免疫功能,有利于感染控制,并降低住院死亡率。
Objective: To investigate the effect and clinical significance of thymosin α1 on cellular immune function in elderly patients with severe hospital acquired pneumonia (SHAP). Methods: Forty-eight patients with SHAP were randomly divided into treatment group and control group. The treatment group was given thymosin α1 1.6 mg subcutaneously on the basis of the control group, qd for 1 week, then changed to 1.6 mg, subcutaneously, every other day for 2 weeks. Results: After treatment, the ratio of HLA-DR, NK cells, CD4 + cells and CD4 + / CD8 + in mononuclear cells increased significantly in treatment group. The in-hospital mortality rate in treatment group was significantly lower than that in control group. Application time is also significantly shorter than the control group. Conclusion: Thymosin α1 can enhance the immune function of patients with SHAP, is conducive to infection control, and reduce in-hospital mortality.